Actelsar HCT

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
24-10-2023
产品特点 产品特点 (SPC)
24-10-2023
公众评估报告 公众评估报告 (PAR)
26-03-2013

有效成分:

Telmisartan, hydrochlorothiazide

可用日期:

Actavis Group hf

ATC代码:

C09DA07

INN(国际名称):

telmisartan, hydrochlorothiazide

治疗组:

Agents acting on the renin-angiotensin system, Angiotensin II antagonists and diuretics

治疗领域:

Essential Hypertension

疗效迹象:

Treatment of essential hypertension.Actelsar HCT fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Actelsar HCT 80 mg / 12.5 mg (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.

產品總結:

Revision: 17

授权状态:

Authorised

授权日期:

2013-03-13

资料单张

                                73
B. PACKAGE LEAFLET
74
PACKAGE LEAFLET: INFORMATION FOR THE USER
ACTELSAR HCT 40 MG/12.5 MG TABLETS
telmisartan/hydrochlorothiazide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Actelsar HCT is and what it is used for
2.
What you need to know before you take Actelsar HCT
3.
How to take Actelsar HCT
4.
Possible side effects
5.
How to store Actelsar HCT
6.
Contents of the pack and other information
1.
WHAT ACTELSAR HCT IS AND WHAT IT IS USED FOR
Actelsar HCT is a combination of two active substances, telmisartan
and hydrochlorothiazide in one
tablet. Both of these substances help to control high blood pressure.
-
Telmisartan belongs to a group of medicines called angiotensin II
receptor antagonists.
Angiotensin-II is a substance produced in your body which causes your
blood vessels to narrow
thus increasing your blood pressure. Telmisartan blocks the effect of
angiotensin II so that the
blood vessels relax, and your blood pressure is lowered.
-
Hydrochlorothiazide belongs to a group of medicines called thiazide
diuretics, which cause your
urine output to increase, leading to a lowering of your blood
pressure.
High blood pressure, if not treated, can damage blood vessels in
several organs, which could lead
sometimes to heart attack, heart or kidney failure, stroke, or
blindness. There are usually no symptoms
of high blood pressure before damage occurs. Thus it is important to
regularly measure blood pressure
to verify if it is within the normal range.
ACTELSAR HCT IS USED TO
treat high blood pr
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Actelsar HCT 40 mg/12.5 mg tablets
Actelsar HCT 80 mg/12.5 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Actelsar HCT 40 mg/12.5 mg tablets
Each tablet contains 40 mg telmisartan and 12.5 mg
hydrochlorothiazide.
Actelsar HCT 80 mg/12.5 mg tablets
Each tablet contains 80 mg telmisartan and 12.5 mg
hydrochlorothiazide.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet.
Actelsar HCT 40 mg/12.5 mg tablets
White or almost white, 6.55 x 13.6 mm oval-shaped and biconvex tablets
marked with “TH” on one
side.
Actelsar HCT 80 mg/12.5 mg tablets
White or almost white, 9.0 x 17.0 mm capsule-shaped tablets marked
with “TH 12.5” on both sides.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of essential hypertension.
Actelsar HCT fixed dose combination (40 mg telmisartan/12.5 mg
hydrochlorothiazide and
80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults
whose blood pressure is not
adequately controlled on telmisartan alone.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Posology
Actelsar HCT should be taken in patients whose blood pressure is not
adequately controlled by
telmisartan alone. Individual dose titration with each of the two
components is recommended before
changing to the fixed dose combination. When clinically appropriate,
direct change from monotherapy
to the fixed combination may be considered.
-
Actelsar HCT 40 mg/12.5 mg may be administered once daily in patients
whose blood pressure
is not adequately controlled by telmisartan 40 mg
-
Actelsar HCT 80 mg/12.5 mg may be administered once daily in patients
whose blood pressure
is not adequately controlled by telmisartan 80 mg
Actelsar HCT is also available at the dose strength 80 mg/25 mg
3
_Special populations: _
_Patients with renal impairment _
Periodic monitoring of renal function is advised (see section 4.4).
_Patients with hepatic impairment _
In patients with mild to moderate hepatic impairment the po
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 24-10-2023
产品特点 产品特点 保加利亚文 24-10-2023
公众评估报告 公众评估报告 保加利亚文 26-03-2013
资料单张 资料单张 西班牙文 24-10-2023
产品特点 产品特点 西班牙文 24-10-2023
公众评估报告 公众评估报告 西班牙文 26-03-2013
资料单张 资料单张 捷克文 24-10-2023
产品特点 产品特点 捷克文 24-10-2023
公众评估报告 公众评估报告 捷克文 26-03-2013
资料单张 资料单张 丹麦文 24-10-2023
产品特点 产品特点 丹麦文 24-10-2023
公众评估报告 公众评估报告 丹麦文 26-03-2013
资料单张 资料单张 德文 24-10-2023
产品特点 产品特点 德文 24-10-2023
公众评估报告 公众评估报告 德文 26-03-2013
资料单张 资料单张 爱沙尼亚文 24-10-2023
产品特点 产品特点 爱沙尼亚文 24-10-2023
公众评估报告 公众评估报告 爱沙尼亚文 26-03-2013
资料单张 资料单张 希腊文 24-10-2023
产品特点 产品特点 希腊文 24-10-2023
公众评估报告 公众评估报告 希腊文 26-03-2013
资料单张 资料单张 法文 24-10-2023
产品特点 产品特点 法文 24-10-2023
公众评估报告 公众评估报告 法文 26-03-2013
资料单张 资料单张 意大利文 24-10-2023
产品特点 产品特点 意大利文 24-10-2023
公众评估报告 公众评估报告 意大利文 26-03-2013
资料单张 资料单张 拉脱维亚文 24-10-2023
产品特点 产品特点 拉脱维亚文 24-10-2023
公众评估报告 公众评估报告 拉脱维亚文 26-03-2013
资料单张 资料单张 立陶宛文 24-10-2023
产品特点 产品特点 立陶宛文 24-10-2023
公众评估报告 公众评估报告 立陶宛文 26-03-2013
资料单张 资料单张 匈牙利文 24-10-2023
产品特点 产品特点 匈牙利文 24-10-2023
公众评估报告 公众评估报告 匈牙利文 26-03-2013
资料单张 资料单张 马耳他文 24-10-2023
产品特点 产品特点 马耳他文 24-10-2023
公众评估报告 公众评估报告 马耳他文 26-03-2013
资料单张 资料单张 荷兰文 24-10-2023
产品特点 产品特点 荷兰文 24-10-2023
公众评估报告 公众评估报告 荷兰文 26-03-2013
资料单张 资料单张 波兰文 24-10-2023
产品特点 产品特点 波兰文 24-10-2023
公众评估报告 公众评估报告 波兰文 26-03-2013
资料单张 资料单张 葡萄牙文 24-10-2023
产品特点 产品特点 葡萄牙文 24-10-2023
公众评估报告 公众评估报告 葡萄牙文 26-03-2013
资料单张 资料单张 罗马尼亚文 24-10-2023
产品特点 产品特点 罗马尼亚文 24-10-2023
公众评估报告 公众评估报告 罗马尼亚文 26-03-2013
资料单张 资料单张 斯洛伐克文 24-10-2023
产品特点 产品特点 斯洛伐克文 24-10-2023
公众评估报告 公众评估报告 斯洛伐克文 26-03-2013
资料单张 资料单张 斯洛文尼亚文 24-10-2023
产品特点 产品特点 斯洛文尼亚文 24-10-2023
公众评估报告 公众评估报告 斯洛文尼亚文 26-03-2013
资料单张 资料单张 芬兰文 24-10-2023
产品特点 产品特点 芬兰文 24-10-2023
公众评估报告 公众评估报告 芬兰文 26-03-2013
资料单张 资料单张 瑞典文 24-10-2023
产品特点 产品特点 瑞典文 24-10-2023
公众评估报告 公众评估报告 瑞典文 26-03-2013
资料单张 资料单张 挪威文 24-10-2023
产品特点 产品特点 挪威文 24-10-2023
资料单张 资料单张 冰岛文 24-10-2023
产品特点 产品特点 冰岛文 24-10-2023
资料单张 资料单张 克罗地亚文 24-10-2023
产品特点 产品特点 克罗地亚文 24-10-2023

查看文件历史